Revance Therapeutics Inc (RVNC)

[DewDiligence]

Impressive_datum_from_RVNC’s_phase-2_trial_in_upper_facial_lines: zero cases of ptosis, at any of the three doses, among the 48 subjects tested. The duration of effect was similar to what has been seen in other Daxi trials.

In this trial, “upper facial lines” included glabellar lines, horizontal forehead lines, and crow’s feet.

RVNC is not planning to seek marketing approval in horizontal forehead lines and crow’s feet, so the purpose of this trial was to provide data for injectors who want to treat areas of the upper face other than glabellar lines on an off-label basis.